Von Willebrand factor (Recombinant)

伏尼凝血素α

Report date: 2026/04/08 15:32:22

Base Information

Drug NameVon Willebrand factor (Recombinant)
Drug Alias NameRecombinant von Willebrand factor重组血管假性血友病因子Vonicogum alfa (Baxalta)重组血管性血友病因子Vonicog alfa (Baxalta) +[15] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor VIII stimulantsVon willebrand factor replacementsBlood coagulation pathway activation
TargetsCoagulation factor VIII
Therapy Area/Indicationsvon Willebrand Disease, Type 2von Willebrand Disease, Type 1von Willebrand Diseases +[5] 
Global Approved Indicationsvon Willebrand Diseases
Approved Indications in Chinavon Willebrand Diseases
Original Approved Country/TerritoryUnited States
Original Approved Date2015/12/08
Country/TerritoryCzechiaBelgiumBulgaria +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesShire Japan KkTakeda (China) International Trading Co LtdBaxalta Manufacturing Sàrl +[7] 
Inactive CompaniesTakeda (China) Holdings Co LtdTakeda Pharmaceuticals USA IncBaxalta Incorporated
Active Indicationsvon Willebrand Disease, Type 2von Willebrand Disease, Type 1von Willebrand Diseases +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeB02BD10
Related LinksWikipediaKEGG